Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. M. (Hilde) Jalving

Publicaties

Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo.

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol

Abstract 5611: LAG-3 PET imaging in patients with cancer before immune checkpoint inhibitor therapy

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas

Cinova: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer

Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

Lees meer

Pers/media

MEDtalks - Melanoomupdate 2024

Environmental impact to be included in package leaflets accompanying medication

European Oncologists Are Thinking Green

“Green” prescribing may limit the environmental impact of oncology

MEDtalks E-learning; Zeldzame melanomen en huidtumoren

Lees meer